Current concepts in drug-induced mitochondrial toxicity

Current Protocols in Toxicology

Volumn , Issue SUPPL. 40, 2009, Pages

  Nadanaciva, Sashi ^a   Will, Yvonne ^a  

^a PFIZER INC   (United States)

Author keywords

Apoptosis; Drug toxicity; Energy production; Mitochondria; mt ribosomes; mtDNA; ROS; Toxicity

Indexed keywords

2,4 DINITROPHENOL; ANALGESIC AGENT; ANTIANGINA PECTORIS AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; ANTIRETROVIRUS AGENT; BUFORMIN; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; DOXORUBICIN; FENOFIBRATE; LOCAL ANESTHETIC AGENT; NEFAZODONE; NEUROLEPTIC AGENT; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENFORMIN; PIOGLITAZONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; TOLCAPONE; TRICYCLIC ANTIDEPRESSANT AGENT; TROGLITAZONE; UNINDEXED DRUG;

APOPTOSIS; CARDIOMYOPATHY; CARDIOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPLICATION; ELECTRON TRANSPORT; ENERGY METABOLISM; FATTY ACID OXIDATION; FATTY LIVER; GLYCOLYSIS; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTHERMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER TOXICITY; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL TOXICITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RIBOSOME;

ANIMALS; APOPTOSIS; DNA REPLICATION; DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; OXIDATIVE PHOSPHORYLATION; PHARMACEUTICAL PREPARATIONS; REACTIVE OXYGEN SPECIES;

EID: 65549115123     PISSN: 19349254     EISSN: 19349262     Source Type: Journal    
DOI: 10.1002/0471140856.tx0215s40     Document Type: Review

References (50)

1. Adam-Vizi, V. and Chinopoulos, C. 2006. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol. Sci. 27:639-645.
2. Benbrik, E., Chariot, P., Bonavaud, S., Ammi- Said, M., Frisdal, E., Rey, C., Gherardi, R., and Barlovatz-Meimon, G. 1997. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J. Neurol. Sci. 149:19-25.
3. Berman, S.B., Pineda, F.J., and Hardwick, J.M. 2008. Mitochondrial fission and fusion dynamics: The long and short of it. Cell Death Differ. 15:1147-1152.
4. Berson, A., Cazanave, S., Descatoire, V., Tinel, M., Grodet, A., Wolf, C., Feldmann, G., and Pessayre, D. 2006. The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethanesulfoanilide), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: Protection by albumin. Pharmacol. Exp. Ther. 318:444-454.
5. Berthiaume, J.M. and Wallace, K.B. 2007. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 23:15-25.
6. Boelsterli, U.A. 2007. Disruption of mitochondrial function andmitochondria-mediated toxicity In Mechanistic Toxicology (U.A. Boelsterli, ed.) pp. 357-383.
7. Böttger, E.C. 2007. Antimicrobial agents targeting the ribosome: The issue of selectivity and toxicity - Lessons to be learned. Cell. Molec. Life Sci. 64:791-795.
8. Brunmair, B., Lest, A., Staniek, K., Gras, F., Scharf, N., Roden, M., Nohl, H., Waldhäusl, W., and Fürnsinn, C. 2004. Fenofibrate impairs rat mitochondrial function by inhibition of respiratory control complex I. J. Pharmacol. Exp. Ther. 311:109-114.
9. Chan, K., Truong, D., Shangari, N., and O'Brien, P.J. 2005. Drug-induced mitochondrial toxicity. Expert Opin. Drug Metab. Toxicol. 1:655-669.
10. Chipuk, J.E. and Green, D.R. 2008. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 18:157-164.
11. Cunarro, J. and Weiner, M.W. 1975. Mechanism of action of agents which uncouple oxidative phosphorylation: Direct correlation between proton carrying and respiratory-releasing properties using rat liver mitochondria. Biochim. Biophys. Acta 387:234-240.
12. de Baar, M.P. and de Ronde, A. 2008. Mitochondrial toxicity of antiviral drugs: A challenge to accurate diagnosis. In Drug-Induced Mitochondrial Dysfunction (J.A. Dykens and Y.Will, eds.) pp. 473-492.
13. Dykens, J.A., and Will, Y. 2007. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12:777-785.
14. Dykens, J.A., Marroquin, L.D., and Will, Y. 2007. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev. Mol. Diagn. 7:161-175.
15. Dykens, J.A., Jamieson, J.D., Marroquin, L.D., Nadanaciva, S., Xu, J.J., Dunn, M.C., Smith, A.R., and Will, Y. 2008a. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci. 103:335-345.
16. Dykens, J.A., Jamieson, J., Marroquin, L., Nadanaciva, S., Billis, P.A., and Will, Y. 2008b. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol. Appl. Pharmacol. 233:203-210.
17. Green, D.R. 2005. Apoptotic pathways: Ten minutes to dead. Cell. 121:671-674.
18. Haasio, K., Koponen, A., Penttilä, K.E., and Nissinen, E. 2002. Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol. 453:21-26.
19. Han, D., Matsumaru, K., Rettori, D., and Kaplowitz, N. 2004. Usnic acid-induced necrosis of cultured mouse hepatocytes: Inhibition of mitochondrial function and oxidative stress. Biochem. Pharmacol. 67:439-451.
20. Kaufmann, P., Torok, M., Zahno, A., Waldhauser, K.M., Brecht, K., and Krahenbuhl, S. 2006. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol. Life Sci. 63:2415-2425.
21. Kinnally, K.W. and Antonsson, B. 2007. A tale of two mitochondrial channels, MAC and PTP, in apoptosis. Apoptosis 12:857-868.
22. Kroemer, G., Galluzzi, L., and Brenner, C. 2007. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87:99-163.
23. Krueger, M.J., Singer, T.P., Casida, J.E., and Ramsay, R.R. 1990. Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone. Biochem. Biophys. Res. Commun. 169:123-128.
24. Labbe, G., Pessayre, D., and Fromenty, B. 2008. Drug-induced liver injury through mitochondrial dysfunction: Mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 22:335-353.
25. Lee, J., Sharma, S., Kim, J., Ferrante, R.J., and Ryu, H. 2008. Mitochondrial nuclear receptors and transcription factors: Who's minding the cell? J. Neurosci. Res. 86:961-971.
26. Liébecq, C. and Peters, R.A. 1989. The toxicity of fluoroacetate and the tricarboxylic acid cycle. Biochim. Biophys. Acta. 1000:254-269.
27. Masubuchi, Y., Nakayama, S., and Horie, T. 2002. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35:544-551.
28. Masubuchi, Y., Kano, S., and Horie, T. 2006. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 222:233-239.
29. Maurer, I. and Möller, H.J. 1997. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell Biochem. 174:255-259.
30. McKee, E.E. 2008. Assessing mitochondrial protein synthesis in drug toxicity screening. In Drug-Induced Mitochondrial Dysfunction (J.A. Dykens and Y. Will, eds.) pp. 463-472. John Wiley & Sons, Inc., Hoboken, N.J.
31. McKee, E.E., Ferguson, M., Bentley, A.T., and Marks, T.A. 2006. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrobial Agents Chemo. 50:2042-2049.
32. Mehta, R., Chan, K., Lee, O., Tafazoli, S., and O'Brien, P.J. 2008. Drug-associated mitochondrial toxicity. In Drug-Induced Mitochondrial Dysfunction (J.A. Dykens and Y.Will, eds.) pp. 71-126. JohnWiley & Sons, Inc., Hoboken, N.J.
33. Modjtahedi, N., Giordanetto, F., Madeo, F., and Kroemer, G. 2006. Apoptosis-inducing factor: Vital and lethal. Trends Cell Biol. 16:264-272.
34. Nadanaciva, S., Dykens, J.A., Bernal, A., Capaldi, R.A., and Will, Y. 2007. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol. Appl. Pharmacol. 223:277-287.
35. Ong, M.M., Latchoumycandane, C., and Boelsterli, U.A. 2007. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci. 97:205-213.
36. Ow, Y.L., Green, D.R., Hao, Z., and Mak, T.W. 2008. Cytochrome c: Functions beyond respiration. Nat. Rev. Mol. Cell Biol. 9:532-542.
37. Pagliarini, D.J., Calvo, S.E., Chang, B., Sheth, S.A., Vafai, S.B., Ong, S.E., Walford, G.A., Sugiana, C., Boneh, A., Chen, W.K., Hill, D.E., Vidal, M., Evans, J.G., Thorburn, D.R., Carr, S.A., and Mootha, V.K. 2008. A mitochondrial protein compendium elucidates complex I disease biology. Cell 134:112-123.
38. Psarra, A.M. and Sekeris, C.E. 2008. Nuclear receptors and other nuclear transcription factors in mitochondria: Regulatory molecules in a new environment. Biochim. Biophys. Acta 1783:1-11.
39. Scatena, R., Bottoni, P., Botta, G., Martorana, G.E., and Giardina, B. 2007. The role of mitochondria in pharmacotoxicology: A reevaluation of an old, newly emerging topic. Am. J. Physiol. Cell Physiol. 293:C12-C21.
40. Scheffler, I.E. 2007. Mitochondrial electron transfer and oxidative phosphorylation. In Mitochondria (I.E. Scheffler, ed.) pp. 168-297. John Wiley & Sons, Inc., Hoboken, N.J.
41. Scheffler, I.E., 2008. Basic molecular biology of mitochondrial replication In Drug-Induced Mitochondrial Dysfunction (J.A. Dykens and Y. Will, eds.) pp. 37-70. John Wiley & Sons, Inc., Hoboken, N.J.
42. Tay, V.K., Wang, A.S., Leow, K.Y., Ong, M.M., Wong, K.P., and Boelsterli, U.A. 2005. Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic. Biol. Med. 39:949-959.
43. Taylor, S.W., Fahy, E., Zhang, B., Glenn, G.M., Warnock, D.E., Wiley, S., Murphy, A.N., Gaucher, S.P., Capaldi, R.A., Gibson, B.W., and Ghosh, S.S. 2003. Characterization of the human heart mitochondrial proteome. Nat. Biotechnol. 21:281-286.
44. Tirmenstein, M.A., Hu, C.X., Gales, T.L., Maleeff, B.E., Narayanan, P.K., Kurali, E., Hart, T.K., Thomas, H.C., and Schwartz, L.W. 2002. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 69:131-138.
45. Turrens, J.F. 2003. Mitochondrial formation of reactive oxygen species. J. Physiol. 552:335-344.
46. Wallace, K.B. 2008. Mitochondrial off targets of drug therapy. Trends Pharmacol. Sci. 29:361-366.
47. Wallace, K.B. and Starkov, A. 2000. Mitochondrial targets of drug toxicity. Ann. Rev. Pharmacol. Toxicol. 40:353-388.
48. Wang, D.S., Kusuhara, H., Kato, Y., Jonker, J.W., Schinkel,A.H., and Sugiyama,Y. 2003. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol. Pharmacol. 63:844-848.
49. Wojtczak, L. and Zablocki, K. 2008. Basic mitochondrial physiology in cell viability and death. In Drug-Induced MitochondrialDysfunction (J.A. Dykens and Y. Will, eds.) pp. 3-35. John Wiley & Sons, Inc., Hoboken, N.J.
50. Zhou, S. and Wallace, K.B. 1999. The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol. Sci. 48:82-89.